These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 22681773)

  • 1. Antibody mediated rejection associated with complement factor h-related protein 3/1 deficiency successfully treated with eculizumab.
    Noone D; Al-Matrafi J; Tinckam K; Zipfel PF; Herzenberg AM; Thorner PS; Pluthero FG; Kahr WH; Filler G; Hebert D; Harvey E; Licht C
    Am J Transplant; 2012 Sep; 12(9):2546-53. PubMed ID: 22681773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Eculizumab Therapy for Atypical Hemolytic Uremic Syndrome Recurrence and Antibody-Mediated Rejection Progress After Renal Transplantation With Preformed Donor-Specific Antibodies: Case Report.
    Yamamoto T; Watarai Y; Futamura K; Okada M; Tsujita M; Hiramitsu T; Goto N; Narumi S; Takeda A; Kobayashi T
    Transplant Proc; 2017; 49(1):159-162. PubMed ID: 28104125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful discontinuation of eculizumab under immunosuppressive therapy in DEAP-HUS.
    Hackl A; Ehren R; Kirschfink M; Zipfel PF; Beck BB; Weber LT; Habbig S
    Pediatr Nephrol; 2017 Jun; 32(6):1081-1087. PubMed ID: 28220235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Report of the inefficacy of eculizumab in two cases of severe antibody-mediated rejection of renal grafts.
    Burbach M; Suberbielle C; Brochériou I; Ridel C; Mesnard L; Dahan K; Rondeau E; Hertig A
    Transplantation; 2014 Nov; 98(10):1056-9. PubMed ID: 24839895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful treatment of DEAP-HUS with eculizumab.
    Noone D; Waters A; Pluthero FG; Geary DF; Kirschfink M; Zipfel PF; Licht C
    Pediatr Nephrol; 2014 May; 29(5):841-51. PubMed ID: 24249282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Heterozygous CFHR3-CFHR1 Gene Deletion in a Pediatric Patient With Transplant-associated Thrombotic Microangiopathy Who was Treated With Eculizumab.
    Nozawa A; Ozeki M; Hori T; Kawamoto N; Hirayama M; Azuma E; Fukao T
    J Pediatr Hematol Oncol; 2018 Nov; 40(8):e544-e546. PubMed ID: 28991129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eculizumab for Treatment of Refractory Antibody-Mediated Rejection in Kidney Transplant Patients: A Single-Center Experience.
    Yelken B; Arpalı E; Görcin S; Kocak B; Karatas C; Demiralp E; Turkmen A
    Transplant Proc; 2015; 47(6):1754-9. PubMed ID: 26293046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eculizumab and Belatacept for De Novo Atypical Hemolytic Uremic Syndrome Associated With CFHR3-CFHR1 Deletion in a Kidney Transplant Recipient: A Case Report.
    Dedhia P; Govil A; Mogilishetty G; Alloway RR; Woodle ES; Abu Jawdeh BG
    Transplant Proc; 2017; 49(1):188-192. PubMed ID: 28104134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of eculizumab in a systemic lupus erythemathosus patient presenting thrombotic microangiopathy and heterozygous deletion in CFHR1-CFHR3. A case report and systematic review.
    de Holanda MI; Pôrto LC; Wagner T; Christiani LF; Palma LMP
    Clin Rheumatol; 2017 Dec; 36(12):2859-2867. PubMed ID: 28905254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients.
    Stegall MD; Diwan T; Raghavaiah S; Cornell LD; Burns J; Dean PG; Cosio FG; Gandhi MJ; Kremers W; Gloor JM
    Am J Transplant; 2011 Nov; 11(11):2405-13. PubMed ID: 21942930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Living Donor Kidney Transplantation in Atypical Hemolytic Uremic Syndrome: A Case Series.
    Duineveld C; Verhave JC; Berger SP; van de Kar NCAJ; Wetzels JFM
    Am J Kidney Dis; 2017 Dec; 70(6):770-777. PubMed ID: 28821363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eculizumab treatment of acute antibody-mediated rejection in renal transplantation: case reports.
    González-Roncero F; Suñer M; Bernal G; Cabello V; Toro M; Pereira P; Angel Gentil M
    Transplant Proc; 2012 Nov; 44(9):2690-4. PubMed ID: 23146495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acquired thrombotic thrombocytopenic purpura with isolated CFHR3/1 deletion-rapid remission following complement blockade.
    Bitzan M; Hammad RM; Bonnefoy A; Al Dhaheri WS; Vézina C; Rivard GÉ
    Pediatr Nephrol; 2018 Aug; 33(8):1437-1442. PubMed ID: 29728803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemolytic uremic syndrome with dual caution in an infant: cobalamin C defect and complement dysregulation successfully treated with eculizumab.
    Barlas UK; Kıhtır HS; Goknar N; Ersoy M; Akcay N; Sevketoglu E
    Pediatr Nephrol; 2018 Jun; 33(6):1093-1096. PubMed ID: 29558000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atypical HUS associated with severe, unexpected antibody-mediated rejection post kidney transplant.
    Stevenson S; Mallett A; Oliver K; Hyland V; Hawley C; Malmanche T; Isbel N
    Nephrology (Carlton); 2014 Apr; 19 Suppl 1():22-6. PubMed ID: 24460647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
    Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
    Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atypical hemolytic uremic syndrome associated with complement factor H autoantibodies and CFHR1/CFHR3 deficiency.
    Lee BH; Kwak SH; Shin JI; Lee SH; Choi HJ; Kang HG; Ha IS; Lee JS; Dragon-Durey MA; Choi Y; Cheong HI
    Pediatr Res; 2009 Sep; 66(3):336-40. PubMed ID: 19531976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factor H-related protein 1 neutralizes anti-factor H autoantibodies in autoimmune hemolytic uremic syndrome.
    Strobel S; Abarrategui-Garrido C; Fariza-Requejo E; Seeberger H; Sánchez-Corral P; Józsi M
    Kidney Int; 2011 Aug; 80(4):397-404. PubMed ID: 21677636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eculizumab for salvage treatment of refractory antibody-mediated rejection in kidney transplant patients: case reports.
    Kocak B; Arpali E; Demiralp E; Yelken B; Karatas C; Gorcin S; Gorgulu N; Uzunalan M; Turkmen A; Kalayoglu M
    Transplant Proc; 2013 Apr; 45(3):1022-5. PubMed ID: 23622614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of Eculizumab for Active Antibody-mediated Rejection That Occurs Early Post-kidney Transplantation: A Consecutive Series of 15 Cases.
    Tan EK; Bentall A; Dean PG; Shaheen MF; Stegall MD; Schinstock CA
    Transplantation; 2019 Nov; 103(11):2397-2404. PubMed ID: 30801549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.